Efficacy and Safety of Sabatolimab in Combination with Hypomethylating Agents in Patients with Very High/High-Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia: Final Analysis from a Phase Ib Study

Supplementary material for associated oral presentation
Durability of response: Sabatolimab + HMA in vHR/HR-MDS

CR, complete remission; EOT, end of treatment; H, high; HI, hematologic improvement; IPSS-R, Revised international Prognostic Scoring System; mCR, bone marrow CR; MDS, myelodysplastic syndrome; PD, progressive disease; PR, partial remission; SD, stable disease; VH, very high.

Oral presentation at the 2021 ASH Annual Meeting & Exposition, held 11–14 December 2021